Tavanta is addressing serious medical disorders with limited treatment options by creating novel therapies to improve patients’ lives.

We are currently evaluating commercial opportunites for our late-stage asset, TAVT-45, for prostate cancer.

Our late-stage colorectal product targets anal fissure, a common and very painful condition.

Under our respiratory franchise, we are developing peptide conjugates with an initial focus on cystic fibrosis.

Program
Indication
  • Discovery
  • Pre-ind
  • Ph 1
  • Ph 2
  • Ph 3
  • Approval
TAVT-45 TAVT-45
Prostate Cancer
Prostate Cancer
  • APPROVAL
TAVT-119 TAVT-119
Chronic Anal Fissures
Chronic Anal Fissures
  • PH3
TAVT-135 TAVT-135
Cystic Fibrosis
Cystic Fibrosis
  • PRE-IND
Other respiratory Other respiratory
  • DISCOVERY